← Back to all trials
Recruiting
NCT06459141
The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
Conditions: Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 150
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Location: The Second Affiliated Hospital of Zhejiang University anesthesiology department Hangzhou Zhejiang
Summary
The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.
Eligibility Criteria
Inclusion Criteria:
1. age 18 to 75 years;
2. undergoing elective bone tumor resection surgery;
3. preoperative hemoglobin ≥11 g/dL;
Exclusion Criteria:
1. using a tourniquet;
2. palliative operation or minimally invasive surgery;
3. BMI\30Kg/m\^2;
4. international normalized ratio (INR) \>1.5 or platelet count \
Source: ClinicalTrials.gov (NCT06459141). StuddyBuddy aggregates publicly available trial information.
